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Human Papillomaviruses (HPV) are responsible for several diseases and some of them (such as HPV16 and HPV18) can induce cervical cancer. In this case the two HPV E6 and E7 oncoproteins are essential players in order to immortalize keratinocytes by decreasing tumor suppressor genes (p53 and pRb). Nowadays cervical cancer is known to be the third most frequent cause of death in women and only prophylactics vaccines exist. Except classical cancer therapy (surgery and radio/chemotherapy), there is no more treatment if the lesion is already developed.
Gene therapy is a promising strategy to treat cancer. We focus on RNA interferences (siRNA) to target mRNA coding for both HPV E6 and E7 oncoproteins. siRNA would be encapsulated in cationic lipidic nanovectors to form lipoplexes. This association is essential to protect siRNA, to allow the diffusion into the vaginal mucus and to cross the anionic cellular membrane.
The aim of this study is to develop a local treatment of cervical cancer by siRNA antiE6 and/or antiE7 that would be encapsulated in cationic nanovectors.
In the first time, we validated the efficacy of both siRNA antiE6 and antiE7 with a commercially transfection agent (Oligofectamine®). Some objectives are achieved: high transfection, extinction of E6 and E7 mRNA and decreased proliferation of cells. However, the induction of apoptosis is quite low. To enhance the rate of cell death, we will trigger an anti-apoptotic protein with another siRNA.

In the second time, Oligofectamine® had been replaced by liposomes with good physicochemical characteristics (size, surface charge, stability…). Liposomes composed of DOTAP/DOPE/Cholesterol (1:0,5:0,5; molar ratio) are preformed and then mixed with siRNA (100 nM; N/P 5). The size of obtained lipoplexes is around 200nm and the zeta potential is around +45mV. This formulation leads a very efficient transfection (FACS Analysis). Moreover, a promising efficacy was obtained as the percentage of mRNA is significantly reduced (qPCR analysis). However, lipoplexes seem to be more toxic (Fixable Viability Stain 450) than Oligofectamine® complexed with siRNA. In order to decrease this toxicity, a reduced concentration of lipoplexes was tested. We showed that at a lower concentration, we were able to reduce toxicity while the efficacy remains the same.

In conclusion, even if the results are hopeful, some other tests will have to be done to validate the efficacy of lipoplexes. Especially, the decrease of proliferation, the induction of apoptosis and the safety on cells will have to be confirmed. The formulation will then be optimized to obtain the best efficacy/toxicity ratio.
Finally, we have developed a 3D model of cervical lesion and lipoplexes will be inoculated on it. We will analyze the safety of lipoplexes, its diffusion into the pluristratified epithelium, and the action of the loaded siRNA. 



